- Home
- IRON
IRON
Disc Medicine Inc.
as of 12-08-2025 12:38pm EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $108.83 | AVG Volume (30 days): | 533.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.82 - $97.11 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered IRON Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
Chief Operating Officer
Avg Cost/Share
$84.59
Shares
30,000
Total Value
$2,540,922.64
Owned After
62,540
10% Owner
Avg Cost/Share
$80.47
Shares
744,047
Total Value
$59,873,462.09
Owned After
2,814,379
SEC Form 4
Director
Avg Cost/Share
$88.51
Shares
70,000
Total Value
$6,223,933.59
Owned After
385,999
Director
Avg Cost/Share
$77.11
Shares
1,425
Total Value
$109,881.75
Owned After
385,999
SEC Form 4
Director
Avg Cost/Share
$77.46
Shares
22,160
Total Value
$1,711,436.40
Owned After
385,999
Director
Avg Cost/Share
$70.40
Shares
71,961
Total Value
$5,079,007.12
Owned After
385,999
Director
Avg Cost/Share
$68.51
Shares
18,039
Total Value
$1,233,493.39
Owned After
385,999
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Yu Jonathan Yen-Wen | IRON | Chief Operating Officer | Nov 11, 2025 | Sell | $84.59 | 30,000 | $2,540,922.64 | 62,540 | |
| AI DMI LLC | IRON | 10% Owner | Oct 22, 2025 | Sell | $80.47 | 744,047 | $59,873,462.09 | 2,814,379 | |
| Bitterman Kevin | IRON | Director | Oct 17, 2025 | Sell | $88.51 | 70,000 | $6,223,933.59 | 385,999 | |
| Bitterman Kevin | IRON | Director | Oct 16, 2025 | Sell | $77.11 | 1,425 | $109,881.75 | 385,999 | |
| Bitterman Kevin | IRON | Director | Oct 15, 2025 | Sell | $77.46 | 22,160 | $1,711,436.40 | 385,999 | |
| Bitterman Kevin | IRON | Director | Oct 8, 2025 | Sell | $70.40 | 71,961 | $5,079,007.12 | 385,999 | |
| Bitterman Kevin | IRON | Director | Oct 7, 2025 | Sell | $68.51 | 18,039 | $1,233,493.39 | 385,999 |
Compare IRON vs Leading Stocks
See how IRON stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.